Compare Summit Therapeutics Inc (SMMT) vs Zillow Group Inc Class C (Z) Price & Performance

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.

Zillow Group (Z) trades at $32.36, down 6.45% amid a challenging housing market. The stock shows bearish technical signals with support at $30 and resistance at $34. Fundamentally, revenue growth continues (2025: $2.58B, 2026: $2.8B projected) with improving profitability (net margin turning positive at 1.96% in 2025). Recent Q2 2026 earnings beat expectations with $0.52 EPS versus $0.4459 expected, though the company faces regulatory scrutiny from a recent FTC settlement.

Despite near-term headwinds, Zillow's transition to an integrated transaction platform and strong rental market presence offer long-term growth potential. Key risks include housing market volatility, competitive pressures, and ongoing legal challenges. Analyst consensus price target of $52 suggests significant upside potential from current levels, though technical indicators remain bearish in the short term.